Aspire BioPharma is trading 5.52% down at $7.36 in pre-market, with no clear overnight negative company-specific catalyst identified.
- It closed at $7.79 on August 10, 2026.
- The company announced completion of its $30 million acquisition of Dura Driver Control Systems and a $22.5 million revolving credit facility; the news does not directly explain the decline.
- Broader markets are modestly higher, making a global-market explanation unlikely.